Cardiovascular pharmacotherapy and real-world data.
作者信息
Agewall Stefan
机构信息
Editor-in-Chief, Oslo University Hospital Ullevål and Institute of Clinical Sciences, University of Oslo, Oslo, Norway.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):65-66. doi: 10.1093/ehjcvp/pvy008.
PMID:29554294
Abstract
摘要
相似文献
1
Cardiovascular pharmacotherapy and real-world data.心血管药物治疗与真实世界数据。
Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):65-66. doi: 10.1093/ehjcvp/pvy008.
2
Cardiovascular pharmacotherapy.心血管药物治疗
Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):1. doi: 10.1093/ehjcvp/pvx036.
3
Cardiovascular pharmacotherapy-2015 was a good year.2015年是心血管药物治疗的丰收之年。
Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):209-11. doi: 10.1093/ehjcvp/pvw020.
4
Old and new drugs in cardiovascular pharmacotherapy.心血管药物治疗中的新药与旧药
Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):1-2. doi: 10.1093/ehjcvp/pvy046.
5
Abstracts of the 11th International Congress on Cardiovascular Pharmacotherapy. Montreal, Canada, 18-21 May 2002.第十一届国际心血管药物治疗大会摘要。加拿大蒙特利尔，2002年5月18日至21日。
Cardiovasc Drugs Ther. 2002;16 Suppl 1:5-116.
6
Abstracts of the 10th International Congress on Cardiovascular Pharmacotherapy. Kyoto, Japan, 27-31 March 2001.第十届国际心血管药物治疗大会摘要。日本京都，2001年3月27日至31日。
Cardiovasc Drugs Ther. 2001 Mar;15 Suppl 1:1-166.
7
The application to MEDLINE from European Heart Journal-Cardiovascular Pharmacotherapy has been accepted!《欧洲心脏杂志 - 心血管药物治疗》向医学文献数据库（MEDLINE）的投稿已被接受！
Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):207-8. doi: 10.1093/ehjcvp/pvw021.
8
European Heart Journal - Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723.《欧洲心脏杂志 - 心血管药物治疗》获得了首个6.723的影响因子。
Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):183-184. doi: 10.1093/ehjcvp/pvz041.
9
Cardiovascular pharmacotherapy 2010: foreword.《心血管药物治疗学2010》：前言
Cardiovasc Drugs Ther. 2010 Aug;24(4):297. doi: 10.1007/s10557-010-6260-x.
10
European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition.《欧洲心脏杂志-心血管药物治疗》2016年：进入国际认可的新高度。
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):3-4. doi: 10.1093/ehjcvp/pvw024.
引用本文的文献
1
The trialist's perspective: what do you need to prove for remote monitoring devices to be approved?试验者的观点：要使远程监测设备获得批准，你需要证明什么？
Eur Heart J Suppl. 2019 Dec;21(Suppl M):M57-M60. doi: 10.1093/eurheartj/suz214. Epub 2019 Dec 31.
2
Left ventricular function monitoring in heart failure.心力衰竭中的左心室功能监测
Eur Heart J Suppl. 2019 Dec;21(Suppl M):M17-M19. doi: 10.1093/eurheartj/suz218. Epub 2019 Dec 31.
3
Heart rate and blood pressure monitoring in heart failure.心力衰竭中的心率和血压监测
Eur Heart J Suppl. 2019 Dec;21(Suppl M):M13-M16. doi: 10.1093/eurheartj/suz217. Epub 2019 Dec 31.
4
Monitoring of biomarkers in heart failure.心力衰竭生物标志物的监测
Eur Heart J Suppl. 2019 Dec;21(Suppl M):M5-M8. doi: 10.1093/eurheartj/suz215. Epub 2019 Dec 31.
5
Physiological monitoring in the complex multi-morbid heart failure patient - Introduction.复杂多病态心力衰竭患者的生理监测——引言
Eur Heart J Suppl. 2019 Dec;21(Suppl M):M1-M4. doi: 10.1093/eurheartj/suz229. Epub 2019 Dec 31.
Zotero 插件